Robbins Umeda LLP Announces An Investigation Of Pharmaceutical Product Development, Inc.
Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Pharmaceutical Product Development, Inc. ("PPD") (NASDAQ: PPDI) in connection with their efforts to sell the company to the Carlyle Group and Hellman & Friedman.
On October 3, 2011, PPD announced that it had entered into a definitive merger agreement pursuant to which affiliates of the Carlyle Group and Hellman & Friedman will acquire all outstanding shares of the company in an all cash transaction, after which PPD will become a privately held company. According to the terms of the deal, shareholders will receive $33.25 for each share of PPD they own. The transaction is expected to close in the fourth quarter of 2011.
Robbins Umeda LLP's investigation focuses on whether PPD's board is undertaking a fair process to obtain maximum value and adequately compensate shareholders in light of the company's recent positive financial results. On July 26, 2011, the company announced second quarter results for fiscal year 2011 that beat analyst expectations. PPD also reported diluted EPS of $0.41, a 127.7% increase compared to the $0.18 of EPS reported during the same period last year, and above analyst estimates of $0.38 of EPS. Further, PPD reported second quarter revenue for fiscal year 2011 of $407.70 million, 10.21% increase over the $369.92 million reported during the same period in the prior year and above analyst estimates of $370.89 million.
If you own stock in PPD and would like more information about your shareholder rights, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or via the shareholder information form on the firm's website.Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more information, please go to http://www.robbinsumeda.com. Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/goodrich-corporation/ Attorney Advertising.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV